On Thursday, Needham, a well-known investment firm, increased its stock price target for Veracyte, Inc (NASDAQ:VCYT) to $44, up from the previous target of $37, while maintaining a Buy rating on the stock. This adjustment followed Veracyte's third-quarter financial performance, which surpassed market expectations.
Veracyte's revenue for the third quarter of 2024 showed a year-over-year increase of 29%, up from 27% in the previous quarter. This growth was attributed primarily to robust performance in Decipher and Afirma testing. However, it was noted that there were declines in Biopharma and Product revenue.
Despite these declines, the company's non-GAAP gross margin improved by 130 basis points year-over-year, and its non-GAAP operating margin saw a significant increase of 900 basis points over the same period.
The firm's decision to raise the price target is based on Veracyte's updated revenue guidance for 2024, which management has revised upwards. This new guidance reflects the company's stronger-than-anticipated revenue trajectory.
The analyst from Needham cited the company's third-quarter revenue and non-GAAP EPS, which both exceeded consensus estimates, as key factors in their decision to reiterate the Buy rating. The improved revenue growth rate in the third quarter was also a contributing factor.
In summary, the price target increase to $44 from $37 is a reflection of the analyst's increased sales estimate for the year 2025 and Veracyte's enhanced revenue growth. The firm's outlook on Veracyte remains positive, as indicated by the maintained Buy rating.
In other recent news, Veracyte has been the subject of several significant developments. The genomic diagnostics company reported a 27% increase in revenue in the second quarter of 2024, reaching $114.4 million, largely due to a surge in testing revenue from its Decipher and Afirma tests. Veracyte also reported a GAAP net income of $5.7 million and an adjusted EBITDA margin of 21%.
The company has expanded its board of directors with the appointment of Brent Shafer and Tom Miller, Ph.D., bringing a wealth of experience in healthcare and technology. Additionally, Veracyte acquired C2i Genomics and plans to launch an MRD assay in 2026.
On the analyst front, UBS initiated coverage on Veracyte with a Buy rating, recognizing the company's growth prospects, particularly in its core products. Similarly, Scotiabank (TSX:BNS) increased Veracyte's stock price target from $37.00 to $40.00, maintaining a Sector Outperform rating. These recent developments highlight the company's robust growth and strategic initiatives.
InvestingPro Insights
Veracyte's recent financial performance, which exceeded market expectations, is further supported by real-time data from InvestingPro. The company's revenue growth remains strong, with a 23.95% increase over the last twelve months as of Q3 2024, and an even more impressive 28.58% growth in the most recent quarter. This aligns with the analyst's observations of robust performance in key testing areas.
InvestingPro Tips highlight that Veracyte has seen a significant return over the last week and a strong return over the last three months, with the stock trading near its 52-week high. These tips corroborate the positive sentiment expressed in the Needham analyst's report and the increased price target.
The company's financial health appears solid, with InvestingPro data showing that liquid assets exceed short-term obligations and the company operates with a moderate level of debt. This financial stability could provide Veracyte with the flexibility to continue investing in growth initiatives.
It's worth noting that while Veracyte was not profitable over the last twelve months, analysts predict the company will be profitable this year, according to InvestingPro Tips. This expectation aligns with the improved non-GAAP operating margin mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Veracyte, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.